Co-Diagnostics appoints Richard Abbott as President effective March 15, 2024

Co-Diagnostics, Inc.

Richard Abbott, age 52, appointed President of Co-Diagnostics, effective March 15, 2024.
He previously served as President of Advanced Conceptions, a wholly owned subsidiary acquired in December 2021.
Through 50% ownership of Whiteknob LLC, he may earn up to 507,386 common shares and 166,503 warrants upon milestone achievements.
Holds MBA from Wharton and MS/BS in Mechanical Engineering from Brigham Young University.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Richard Abbott

President

CODX · Co-Diagnostics, Inc.

Effective: 2024-03-15
Filed: March 15, 2024, 7:59 PM ET

On March 15, 2024, the Board of Directors of Co-Diagnostics, Inc. (the “Company”) appointed Richard Abbott as President.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Richard Abbott was appointed as President at Co-Diagnostics, Inc..

Action: appointed
Role: President

Exact text from the filing

On March 15, 2024, the Board of Directors of Co-Diagnostics, Inc. (the “Company”) appointed Richard Abbott as President.

View on SEC.gov

Co-Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-010089

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.